Evidence map›Paper›PMID 28881751›Full record

ArticleOncotarget2017

Hepatitis B virus surface proteins accelerate cholestatic injury and tumor progression in Abcb4-knockout mice.

Daniel Zahner, Hannah Glimm, Tomomitsu Matono, Yuri Churin, Diran Herebian, Ertan Mayatepek, Kernt Köhler, Stefan Gattenlöhner, Anne Stinn, Annette Tschuschner and 2 more

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05293158 (Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05293158 naunknown statusnot on this mapstarted 2024, after this paper: background citation

Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma

TypeinterventionalSponsorMedical University of GrazRan2024 to 2026Enrolled5ConditionsHepatocellular Carcinoma, HBVArmsHepatect CP 50 I.E./ml infusion solution
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Fructose and Non-Alcoholic Steatohepatitis.Frontiers in pharmacology · 2021
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Daniel Zahner *Central Laboratory Animal Facility, Justus Liebig University, Giessen, Germany.
Hannah Glimm *Department of Gastroenterology, Justus Liebig University, Giessen, Germany.
Tomomitsu Matono *Department of Gastroenterology, Justus Liebig University, Giessen, Germany.
Yuri ChurinDepartment of Gastroenterology, Justus Liebig University, Giessen, Germany.
Diran HerebianDepartment of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Ertan MayatepekDepartment of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Kernt KöhlerInstitute of Veterinary Pathology, Justus-Liebig-University, Giessen, Germany.
Stefan GattenlöhnerDepartment of Pathology, Justus-Liebig-University, Giessen, Germany.
Anne StinnDepartment of Gastroenterology, Justus Liebig University, Giessen, Germany.
Annette TschuschnerDepartment of Gastroenterology, Justus Liebig University, Giessen, Germany.
Martin RoderfeldDepartment of Gastroenterology, Justus Liebig University, Giessen, Germany.
Elke RoebDepartment of Gastroenterology, Justus Liebig University, Giessen, Germany.
University of Giessen · DEHeinrich Heine University Düsseldorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding of the pathophysiology of cholestasis associated carcinogenesis could challenge the development of new personalized therapeutic approaches and thus improve prognosis. Simultaneous damage might aggravate hepatic injury, induce chronic liver disease and even promote carcinogenesis. We aimed to study the effect of Hepatitis B virus surface protein (HBsAg) on cholestatic liver disease and associated carcinogenesis in a mouse model combining both impairments. Hybrids of Abcb4

conclusionCholestasis-induced STAT3- and JNK-pathways may predispose HBsAg-associated tumorigenesis. Since STAT3- and JNK-activation are well characterized critical regulators for tumor promotion, the potentiation of their activation in hybrids suggests an additive mechanism enhancing tumor incidence.

Indexed as

carcinogenesischolangitisER-stressfibrosisHBsAg

Identifiers

PMID28881751
PMCPMC5581050
OpenAlexW2585145097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.